The STAT3 inhibitor treatment resulted in an intact tibial bone microenvironment with no tumor formation or sclerotic response in mice, whereas the VCaP group showed sclerotic bone tumor response up to 85% (48). Here, STAT3 is linked to bone neoplasm.